Adding the drug bortezomib to chemo for a rare childhood brain tumor
Original title: A Phase Ib Case Series Using Bortezomib With Chemotherapy in Atypical Teratoid/Rhabdoid Tumors.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a first safety test in only a few children.
The short version
A small early study tested adding one more drug to chemo for a rare childhood brain tumor.
What was studied. Six children with a new diagnosis of ATRT took part. ATRT is a fast-growing brain tumor in children. They got a drug called bortezomib along with chemo, to see if it was safe.
What they found. Side effects were no worse than with chemo alone. Two children are alive with no sign of tumor at 37 and 40 months. Three children died as their tumor grew.
What this means, and what it doesn't
What it could mean: Doctors may be able to add this drug to chemo for ATRT without causing more harm. That lets larger studies test whether it actually helps.
What it doesn't mean: This does not show that bortezomib works against ATRT. The study had only six children, and it mainly checked safety. It is an early step and far from everyday care. It is not a cure.
Source: PubMed, September 1, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.